Holen Sie sich die Stockscreener-App
1.5146
2.88%
-0.0454
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com
PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com India
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
PACB,TAL Volatility & Greeks - Finviz
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Finviz
Intuitive Surgical Expands Direct Operational Presence in Europe - Finviz
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB) - Finviz
Equity awards to Pacific Biosciences (PACB) officer disclosed - Stock Titan
PACB (PACB) grants James R. Gibson II 667,696 options and 333,848 RSUs - Stock Titan
Pacific Biosciences (PACB) officer receives large option and RSU awards - Stock Titan
Large equity grants to PacBio (PACB) executive highlight retention focus - Stock Titan
Christian Henry sells 472,667 PACB shares (PACB) on Form 144 - Stock Titan
PacBio and DNAstack Join Forces to Launch Worldwide HiFi Genome Network Hub - Bitget
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - Yahoo Finance
Pacific Biosciences of California enables automatic epigenetic data in HiFi sequencing runs - Traders Union
Pacific Biosciences of California backs San Diego event to strengthen rare disease awareness - Traders Union
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
PACB,TAL Revenue Breakdown - Finviz
Pacific Biosciences of California joins IRDiRC to advance rare disease research - Traders Union
Vestmark Advisory Solutions Inc. Sells 692,663 Shares of Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pacific Biosciences of California (PACB) Stock Analysis: A 53% Upside Awaits in the Genomic Sequencing Arena - DirectorsTalk Interviews
Pacific Biosciences Of California Files For Mixed Shelf Size - TradingView
[10-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files Annual Report | PACB SEC FilingForm 10-K - Stock Titan
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Joins Forces with DNAstack for Global Genomic Data Collaboration - GuruFocus
Volume Recap: Is Pacific Biosciences of California Inc stock a buy or sell2025 Winners & Losers & Free Reliable Trade Execution Plans - baoquankhu1.vn
PacBio and DNAstack launch first global federated HiFi whole genome dataset to accelerate rare disease research - marketscreener.com
Global genome network to speed answers for rare disease patients - Stock Titan
Pacific Biosciences of California examines technology impact on DNA sequencing insights - Traders Union
Pacific Biosciences COO Sells Shares - Intellectia AI
Why The PacBio (PACB) Narrative Is Shifting Around Fair Value And Long Read Sequencing - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by Zacks Research - MarketBeat
Will Pacific Biosciences of California Inc. outperform tech stocksMarket Movers & Weekly Stock Performance Updates - mfd.ru
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 331,793 Shares - MarketBeat
Van Oene Mark sells PACB shares worth $294,318 By Investing.com - Investing.com Canada
Farmer of Pacific Biosciences sells $79,855 in stock By Investing.com - Investing.com South Africa
Van Oene Mark sells PACB shares worth $294,318 - Investing.com
Farmer of Pacific Biosciences sells $79,855 in stock - Investing.com
5 Must-Read Analyst Questions From PacBio's Q4 Earnings Call - Finviz
PacBio (PACB) Q4 2025 Earnings Call Transcript - AOL.com
PacBio (PACB): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
PacBio stock up on HiFi sequencing adoption for major SUDC research - MSN
PacBio leaders set for TD Cowen health conference webcast - Stock Titan
Pacific Biosciences of California : PACB Q4 2025 Earning Prepared Remarks - marketscreener.com
Exit Recap: Should I invest in Clene Inc before earningsEarnings Risk Summary & Stepwise Swing Trade Plans - baoquankhu1.vn
Pacific Biosciences Faces Turbulent Market Amid Industry Shifts - timothysykes.com
Aug Drivers: Will Pacific Biosciences of California Inc outperform tech stocks2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Pacific Biosciences of California Inc. stock a falling knife or bargain buy2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
How does Pacific Biosciences of California Inc. compare to its peersJuly 2025 Short Interest & Risk Managed Investment Signals - mfd.ru
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript - Insider Monkey
Slammed 28% Pacific Biosciences of California, Inc. (NASDAQ:PACB) Screens Well Here But There Might Be A Catch - 富途牛牛
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.8%What's Next? - MarketBeat
Pacific Biosciences of California: Navigating Market Waves Amid Revenue Hurdles - StocksToTrade
PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears - Finviz
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up - TradingView
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):